Chemocentryx Company Profile

What is the competitive landscape for CHEMOCENTRYX

CHEMOCENTRYX has one approved drug.

There are four US patents protecting CHEMOCENTRYX drugs.

There are one hundred and six patent family members on CHEMOCENTRYX drugs in thirty-nine countries and fifteen supplementary protection certificates in thirteen countries.

Summary for Chemocentryx

International Patents:	106
US Patents:	4
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Chemocentryx

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,445,515		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,906,938		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,951,214		Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,603,356		Y	Y

International Patents for Chemocentryx Drugs

Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	020874
South Korea	20220098754
Argentina	077162
European Patent Office	3078658
Brazil	112021010285

Supplementary Protection Certificates for Chemocentryx Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2381778	17/2022	Austria		PRODUCT NAME: AVACOPAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/21/1605 (MITTEILUNG) 20220119
2381778	SPC/GB22/014	United Kingdom		PRODUCT NAME: AVACOPAN (AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF); REGISTERED: UK EU/1/21/1605(FOR NI) 20220119; UK FURTHER MA ON IPSUM 20220119
2381778	2290502-0	Sweden		PRODUCT NAME: AVACOPAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/21/1605 20220119
2381778	202240009	Slovenia		PRODUCT NAME: AVACOPAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; NATIONAL AUTHORISATION NUMBER: EU/1/21/1605; DATE OF NATIONAL AUTHORISATION: 20220111; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2381778	22C1020	France		PRODUCT NAME: AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1605 20220119

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Chemi Spa
• Chemisch Fbrk Krsslr
• Chemo Research Sl
• Chemocentryx

Pharmaceutical Competitive Landscape Analysis: ChemoCentryx — Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What is ChemoCentryx’s current market position?

ChemoCentryx operates as a biotech company specializing in developing small-molecule drugs targeting inflammation, autoimmune diseases, and cancer. As of 2023, ChemoCentryx ranked within the top 30 globally among biotech firms focused on rare diseases and inflammation, with a focus on niche therapeutic areas.

The company’s key product, Tavneos (avacopan), received FDA approval in October 2017 for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). It holds regulatory approval in the US, EU, and Japan, positioning it as a significant player in complement pathway inhibitors.

Revenue generated from Tavneos was approximately $120 million in FY 2022, marking a 45% increase from FY 2021, driven by expanding indications and increased market penetration. ChemoCentryx’s pipeline includes several candidates targeting autoimmune and inflammatory diseases, notably the CCX559 and CCX507 compounds.

How does ChemoCentryx compare to competitors?

Company	Key Products	Market Cap (USD billions)	Focus Area	FDA Approvals	Revenue (FY 2022, USD millions)
ChemoCentryx	Tavneos	1.2	Inflammation, Autoimmune	Tavneos, Avacopan	120
GSK	Nucala (mepolizumab)	70.8	Asthma, Rare disease	Multiple	2,786
Alexion (AstraZeneca)	Soliris (eculizumab)	45.1	Complement inhibitors	Multiple	2,101
Regeneron	Dupixent (dupilumab)	50.8	Allergic and inflammatory diseases	Multiple	9,875

ChemoCentryx’s niche focus on complement and cell signaling pathways distinguishes it from larger biotech firms with broader portfolios. Its pipeline embeds small molecules with potential differentiated mechanisms, targeting unmet needs in rare autoimmune disorders.

What are ChemoCentryx’s strengths?

• Innovative Target Portfolio: Focuses on complement pathway modulation and chemokine receptor antagonists, with proven scientific research backing their approaches.
• Regulatory Approval & Market Access: Tavneos’s approval across major markets provides a revenue base and validates its therapeutic approach.
• Pipeline Differentiation: Several pipeline candidates targeting rare and inflammatory diseases have potential to expand indications and drive future growth.
• Partnerships & Collaborations: Strategic alliances with global pharma companies, including Vifor Pharma for Tavneos’s commercialization, bolster market reach.

What strategic challenges does ChemoCentryx face?

• Limited Revenue Base: Revenue remains modest relative to larger peers; scale-up depends on successful commercialization and pipeline success.
• Competitive Landscape: Competes against established biologics (e.g., Soliris) with broader indications and sizable market presence.
• Pipeline Risk: Most pipeline candidates remain in early or mid-stage trials; failure or delays can impact growth.
• Pricing & Reimbursement: As a small-molecule inhibitor, price negotiations and reimbursement policies influence profitability.

What strategic opportunities are available?

• Pipeline Expansion: Advancing candidates like CCX559 (a PD-1/PD-L1 targeted immunotherapy) could open doors to oncology markets.
• Market Penetration: Increased adoption of Tavneos through expanded indications and geographic reach.
• Acquisitions & Collaborations: Targeted acquisitions of complementary assets or partnerships with larger firms to leverage sales and distribution networks.
• Focus on Rare Diseases: Increasing focus on unmet needs in rare autoimmune conditions, with potentially faster regulatory pathways.

What are key regulatory and market trends?

• The global autoimmune disease therapeutics market is projected to grow at a CAGR of 8% through 2027[1].
• Regulatory agencies favor fast-track approvals for innovative therapies addressing unmet needs, providing accelerated pathways for pipeline candidates.
• A shift toward personalized medicine enhances opportunities for targeted small molecule drugs like those developed by ChemoCentryx.
• Growing emphasis on biosimilar and generic competition pressures pharmaceutical companies to innovate.

Key Takeaways

ChemoCentryx holds a strategic position within small-molecule therapeutics targeting inflammatory and autoimmune diseases. Its lead product, Tavneos, has secured regulatory approval and is demonstrated to grow revenue, but the company remains dependent on the success of pipeline candidates for future growth. Competition in complement and immunomodulatory spaces remains intense, with larger biologics firms serving as significant rivals. Strategic focus on pipeline development, geographic expansion, and partnerships will be critical to scaling operations and maintaining market relevance.

FAQs

1. What is ChemoCentryx’s main revenue-generating product?

Tavneos (avacopan), approved for ANCA-associated vasculitis, is the company’s principal commercial asset.

2. How does ChemoCentryx's pipeline compare to competitors?

Its pipeline focuses on rare autoimmune and inflammatory diseases, with several candidates in early development stages. Larger competitors often have broader immunology portfolios and more advanced products.

3. What regulatory hurdles does ChemoCentryx face?

The company faces challenges in securing approvals for pipeline candidates, with potential delays or rejections based on clinical data and safety profiles.

4. How does partnership strategy influence ChemoCentryx’s growth?

Partnerships like that with Vifor Pharma enable broader market access for Tavneos, while collaborations with research institutions support pipeline validation.

5. What is the outlook for ChemoCentryx’s market expansion?

Market expansion depends on approval of additional indications for Tavneos, pipeline maturation, and strategic regional entry.

---

References

[1] MarketsandMarkets. (2023). Autoimmune Disease Therapeutics Market by Disease Type, Therapy, and Region.

[2] FDA. (2022). Tavneos (avacopan) approval letter.

[3] ChemoCentryx. (2023). Annual Report.